Full TitleA Multicenter, Phase 1, Open-label, Dose-Escalation and Expansion Study of TNB-383B, a Bispecific Antibody Targeting BCMA in Subjects with Relapsed or Refractory Multiple Myeloma
The purpose of this study is to assess the safety of the investigational drug TNB-383B in people with multiple myeloma that has come back or continued to grow despite treatment. TNB-383B is called a “bispecific antibody.” It works against cancer by targeting a protein on cancer cells, and it also helps the immune system find and attack multiple myeloma cells. TNB-383B is given intravenously (by vein).
To be eligible for this study, patients must meet several requirements, including:
- Participants must have multiple myeloma that has come back or continued to grow after three or more prior regimens of treatment.
- At least 3 weeks must pass between the completion of previous therapies and receipt of TNB-383B.
- Patients must be able to walk and do routine activities for more than half of their normal waking hours.
- This study is for people age 18 and older.
For more information and to ask about eligibility for this study, please contact the office of Dr. Neha Korde at 646-608-3708.
Relapsed or Refractory